Rapport Therapeutics (RAPP) Research & Development (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Research & Development data on file, last reported at $32.7 million in Q1 2026.

• Research & Development for Q1 2026 came in at $32.7 million, up 67.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.9 million (up 58.72% YoY), and the FY2025 annual result was $94.8 million, up 55.56% from the prior year.
• Research & Development climbed to $32.7 million in Q1 2026 per RAPP's latest filing, from $30.3 million in the prior quarter.
• Over five years, Research & Development peaked at $32.7 million in Q1 2026 and troughed at $4.7 million in Q2 2023.
• A 4-year average of $17.7 million and a median of $16.4 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development surged 232.32% in 2024, then jumped 43.34% in 2025.
• A 4-year view of Research & Development shows it stood at $11.8 million in 2023, then jumped by 45.77% to $17.2 million in 2024, then surged by 75.93% to $30.3 million in 2025, then grew by 8.12% to $32.7 million in 2026.
• Business Quant data shows RAPP's Research & Development at $32.7 million in Q1 2026, $30.3 million in Q4 2025, and $22.3 million in Q3 2025.